Viewing Study NCT04018105


Ignite Creation Date: 2025-12-25 @ 3:28 AM
Ignite Modification Date: 2025-12-31 @ 3:35 PM
Study NCT ID: NCT04018105
Status: UNKNOWN
Last Update Posted: 2022-08-19
First Post: 2019-07-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Influence of Preprandial Metformin Administration on Carbohydrate Absorption
Sponsor: University Hospital, Lille
Organization:

Study Overview

Official Title: Influence of Preprandial Metformin Administration on Carbohydrate Absorption: Pilot Randomized Controlled Study
Status: UNKNOWN
Status Verified Date: 2022-08
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: METTIME
Brief Summary: Type 2 diabetes is spreading worldwide as well as obesity. Metformin is the most prescribed antidiabetic medication. One suggested mechanism of action is by decreasing carbohydrate absorption.

It is usually recommended to take metformin during the meal to decrease gastrointestinal side effects. However, if metformin decreases carbohydrate absorption, this might not be the most efficient intake.

To study the influence of preprandial metformin administration on carbohydrate absorption, it will repeat 3 oral glucose tolerance test on obese dysglycemic patients, without metformin or with metformin administer 30 or 60 minutes before. We will also evaluate how it impacts gastrointestinal tolerance.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2019-001175-36 EUDRACT_NUMBER None View